» Articles » PMID: 32773599

The α2/α3GABAA Receptor Modulator TPA023B Alleviates Not Only the Sensory but Also the Tonic Affective Component of Chronic Pain in Mice

Overview
Journal Pain
Specialties Neurology
Psychiatry
Date 2020 Aug 11
PMID 32773599
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Diminished synaptic inhibition in the spinal dorsal horn is a major contributor to pathological pain syndromes of neuropathic or inflammatory origin. Drugs that enhance the activity of dorsal horn α2/α3GABAARs normalize exaggerated nociceptive responses in rodents with neuropathic nerve lesions or peripheral inflammation but lack most of the typical side effects of less specific GABAergic drugs. It is however still unknown whether such drugs also reduce the clinically more relevant conscious perception of pain. Here, we investigated the effects of the α2/α3GABAAR subtype-selective modulator TPA023B on the tonic aversive component of pain in mice with peripheral inflammation or neuropathy. In neuropathic mice with a chronic constriction injury of the sciatic nerve, TPA023B not only reversed hyperalgesia to tactile and heat stimuli but also was highly effective in the conditioned place preference test. In the formalin test, TPA023B not only reduced licking of the injected paw but also reversed facial pain expression scores in the mouse grimace scale assay. Taken together, our results demonstrate that α2/α3GABAA receptor subtype-selective modulators not only reduce nociceptive withdrawal responses but also alleviate the tonic aversive components of chronic pain.

Citing Articles

γ1 GABA Receptors in Spinal Nociceptive Circuits.

Neumann E, Cramer T, Acuna M, Scheurer L, Beccarini C, Luscher B J Neurosci. 2024; 44(41).

PMID: 39137998 PMC: 11466064. DOI: 10.1523/JNEUROSCI.0591-24.2024.


Spinal cord retinoic acid receptor signaling gates mechanical hypersensitivity in neuropathic pain.

Cao B, Scherrer G, Chen L Neuron. 2022; 110(24):4108-4124.e6.

PMID: 36223767 PMC: 9789181. DOI: 10.1016/j.neuron.2022.09.027.


GABA receptors constrain glutamate presynaptic release and postsynaptic actions in substantia gelatinosa of rat spinal cord.

Zhao M, Shao C, Dong J, Chen Q, Ma R, Jiang P Brain Struct Funct. 2022; 227(5):1893-1905.

PMID: 35318502 DOI: 10.1007/s00429-022-02481-2.


(Franch.) Anderb. Attenuates Nociception and Inflammation GABA Receptors.

Huang C, Dong C, Zhu Y, Yu Y, Jin H, Zhang Y Front Pharmacol. 2021; 12:753128.

PMID: 34795587 PMC: 8592923. DOI: 10.3389/fphar.2021.753128.


GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA receptors.

Cerne R, Lippa A, Poe M, Smith J, Jin X, Ping X Pharmacol Ther. 2021; 234:108035.

PMID: 34793859 PMC: 9787737. DOI: 10.1016/j.pharmthera.2021.108035.


References
1.
Nickolls S, Gurrell R, van Amerongen G, Kammonen J, Cao L, Brown A . Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA receptor positive allosteric modulator PF-06372865. Br J Pharmacol. 2017; 175(4):708-725. PMC: 5786456. DOI: 10.1111/bph.14119. View

2.
Zeilhofer H, Neumann E, Munro G . Corrigendum to 'Spinal GABA receptors for pain control: back to the future?' (Br J Anaesth 2019; 123: e176-9). Br J Anaesth. 2019; 123(6):916. PMC: 6993104. DOI: 10.1016/j.bja.2019.09.003. View

3.
Low K, Crestani F, Keist R, Benke D, Brunig I, Benson J . Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000; 290(5489):131-4. DOI: 10.1126/science.290.5489.131. View

4.
Matsumiya L, Sorge R, Sotocinal S, Tabaka J, Wieskopf J, Zaloum A . Using the Mouse Grimace Scale to reevaluate the efficacy of postoperative analgesics in laboratory mice. J Am Assoc Lab Anim Sci. 2012; 51(1):42-9. PMC: 3276965. View

5.
Engin E, Bakhurin K, Smith K, Hines R, Reynolds L, Tang W . Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens. Neuropsychopharmacology. 2014; 39(8):1805-15. PMC: 4059902. DOI: 10.1038/npp.2014.41. View